Table 1.
Population characteristics according to the results of anti-SARS-COV-2 antibodies and factors associated with seropositivity.
| Total | Reactive | Nonreactive | Crude PR | 95% CI | Adjusted PR | 95% CI | |
|---|---|---|---|---|---|---|---|
| Origin | |||||||
| Urban | 55.2% (2727/4937) |
65.6% (972/1482) |
50.8% (1754/3455) |
1 | 0.58–0.72 | 1 | 0.61–0.76 |
| Rural | 44.8% (2210/4937) |
34.4% (510/1482) |
49.2% (1701/3455) |
0.65 | 0.68 | ||
| Sex | |||||||
| Female | 60.9% (3014/4941) |
63.7% (944/1481) |
59.8% (2070/3460) |
1 | 0.79–0.99 | 1 | 0.81–1.01 |
| Male | 39.0% (1927/4941) |
36.3% (537/1481) |
40.2% (1390/3460) |
0.89 | 0.91 | ||
| Age group (years) | |||||||
| ≥18–30 | 19.9% (1017/5110) |
21.4% (328/1532) |
19.3% (689/3578) |
1 | 0.85–1.10 0.63–0.90 |
1 | 0.83–1.08 0.64–0.91 |
| 30–59 | 58.7% (3001/5110) |
61.3% (939/1532) |
57.7% (2063/3578) |
0.96 | 0.95 | ||
| ≥60 | 21.4% (1092/5110) |
17.3% (265/1532) |
23.1% (826/3578) |
0.75 | 0.76 | ||
| Education level (year) | |||||||
| <7a | 32.4% (1590/4907) |
26.5% (390/1472) |
34.9% (1200/3435) |
1 | 1.08–1.42 1.25–1.64 |
1 | 0.99–1.30 1.02–1.38 |
| 7-11a | 36.0% (1768/4907) |
36.7% (539/1472) |
35.8% (1230/3435) |
1.24 | 1.14 | ||
| 12a or more | 31.6% (1549/4907) |
36.9% (543/1472) |
29.3% (1005/3435) |
1.43 | 1.19 | ||
| People living in the same household: Mean (SE) | 3.98 (0.04) | 4.13 (0.08) | 3.90 (0.05) | 1.02 | 1.01–1.04 | 1.02 | 0.99–1.04 |
| Type of work | |||||||
| In-person | 85,9% (4248/4941) |
87.2% (1291/1481) |
85.5% (2957/3460) |
1 | 0.73–1.13 0.69–1.15 |
1 | 0.64–1.00 0.66–1.11 |
| Remote | 8.8% (435/4941) |
8.1% (120/1481) |
9.1% (315/3460) |
0.91 | 0.80 | ||
| Hybrid | 5.2% (258/491) |
4.7% (70/1481) |
5.5% (188/3460) |
0.89 | 0.86 | ||
| Deceased at home (all causes) | |||||||
| Yes | 3.4% (170/4941) |
3.8% (56/1481) |
3.3% (114/3460) |
1 | 0.81–1.48 | 1 | 0.77–1.39 |
| No | 96.6% (4771/4941) |
96.2% (1425/1481) |
96.7% (3346/3460) |
1.10 | 1.04 | ||
| Hypertension | 4.5% (219/4783) |
4.7% (68/1452) |
4.5% (151/3331) |
1.02 | 0.77–1.35 | 0.97 | 0.74–1.28 |
| Diabetes | 2.5% (119/4769) |
2.5% (36/1444) |
2.5% (83/3325) |
0.98 | 0.66–1.47 | 0.89 | 0.60–1.31 |
| Asthma | 0.8% (36/4750) |
0.9% (12/1442) |
0.7% (24/3308) |
1.14 | 0.59–2.17 | 1.04 | 0.56–1.95 |
| Heart disease | 0.6% (29/4770) |
0.8% (11/1451) |
0.5% (18/3319) |
1.27 | 0.69–2.31 | 1.25 | 0.69–2.25 |
| Cancer | 0.2% (7/4765) |
0.01% (1/1446) |
0.2% (6/3319) |
0.30 | 0.04–2.38 | 0.29 | 0.04–2.35 |
| Respiratory symptoms in the last 14 days | 8.2% (391/4791) |
9.4% (136/1449) |
7.6% (255/3342) |
1.17 | 0.97–1.39 | 1.14 | 0.95–1.37 |
SE, standard error; PR, prevalence ratio; CI, confidence interval;
sex-, urban/rural area- and province-adjusted model.